The Fecal Calprotectin Test Market comprises diagnostic products and services used to measure calprotectin levels in stool to detect intestinal inflammation. These tests support the diagnosis and monitoring of inflammatory bowel diseases (IBD) and help distinguish them from functional disorders like IBS. Market growth is driven by the rising prevalence of gastrointestinal diseases and the increasing demand for non-invasive, accurate diagnostic solutions.
According to FutureWise analysis, the fecal calprotectin test market in 2026 is US$ 4.54 billion and is expected to reach US$ 11.19 billion by 2036 at a CAGR of 9.44%. The growing prevalence of inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, is driving a demand for non-invasive diagnostic tools. Fecal calprotectin testing is gaining importance for its ability to accurately differentiate IBD from irritable bowel syndrome (IBS), reducing the need for invasive procedures like colonoscopy.
Growth Drivers:
- Growing demand for non-invasive and cost-effective diagnostic testing
- Rising awareness about early detection and disease monitoring of gastrointestinal disorders
- Technological advancements in immunoassay and rapid point-of-care testing kits
- Expanding use of fecal calprotectin tests in hospitals, diagnostic laboratories, and home-care settings
- Supportive clinical guidelines recommending calprotectin testing for differentiating IBD from IBS
Key Trends:
- Rising adoption of point-of-care (POC) and rapid testing solutions for quicker clinical decision-making
- Integration of digital health and remote monitoring tools to support at-home testing and patient engagement
- Development of high-sensitivity and automated assay platforms to improve accuracy and throughput
- Growing partnerships between diagnostic manufacturers and healthcare providers to expand market reach
Market Segmentation and Key Players:
The Fecal Calprotectin Test Market is divided by indication, distribution channel, and region. It addresses inflammatory bowel disease (IBD), colorectal cancer, celiac disease, and other gastrointestinal disorders. Distribution channels include hospitals, diagnostic labs, and academic institutes. Geographically, North America leads the market due to its advanced healthcare infrastructure and awareness, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Comprehensive segmentation details are provided in the Segmentation section below.
Major companies operating in the Fecal Calprotectin Test Market include Medix Biochemica, RayBiotech, Inc., and Epitope Diagnostics, Inc.
Research Methodology:
The research methodology for the Fecal Calprotectin Test Market by FutureWise Research uses both primary and secondary research. Secondary research involves analyzing company reports and industry publications, while primary research involves interviewing key stakeholders to validate insights. Market sizing and forecasting are based on historical data analysis, statistical modeling, and data triangulation for accurate estimates.